Siemens Healthineers has introduced two new assays for quick diagnosis of acute myocardial infarction or heart attack, following approval from the US Food and Drug Administration (FDA).

The High-Sensitivity Troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in-vitro diagnostic analysers are designed to detect low cardiac troponin I levels in serum or plasma.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Said to demonstrate 99% precision, the assays can also identify small changes in a patient’s troponin level because of repeat testing.

“According to Siemens, the TnIH assays leverage the company’s technology with three new monoclonal antibodies and are set to provide better patient care with high-sensitivity cardiac troponin detection.”

Early diagnosis is critical as the heart muscle starts dying within 30-60 minutes following the blockage of blood flow to the heart.

Since dying heart muscle releases troponin into the bloodstream, the compound is considered as an indicator of a heart attack.

Out of the more than eight million visits to emergency departments in the US, only 5.5% lead to serious diagnoses such as heart attacks.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The new assays are expected to support testing initiatives by using data to correctly triage patients early or rule out myocardial infarctions.

Zuckerberg San Francisco General Hospital and Trauma Center, Clinical Chemistry and Toxicology chief Alan Wu said: “If we can do a more efficient job at triaging patients to receive the proper level of care and to discharge the patients who do not need to stay in the emergency department, this will have a tremendous economic advantage for our healthcare system.”

According to Siemens, the TnIH assays leverage the company’s technology with three new monoclonal antibodies and are set to provide better patient care with high-sensitivity cardiac troponin detection.

The Siemens portfolio for troponin detection additionally includes Atellica IM, ADVIA Centaur, Dimension EXL and Dimension Vista TNIH assays that are also designed to detect lower troponin levels.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact